小剂量MA方案治疗老年髓性白血病疗效观察.docVIP

精品论文 参考文献 小剂量MA方案治疗老年髓性白血病疗效观察 （北京市第六医院 血液科 邮编100007 ） 　　【摘要】目的：对老年急性髓性白血病患者给予小剂量米托蒽醌和阿糖胞苷（MA）方案治疗效果探讨。方法：选取本院2010年1月—2016年2月间接受的AML患者42例进行研究，将其平均分为两组各21例，给予标准剂量MA方案的患者为标准MA组，给予小剂量MA方案的患者为小剂量MA组。比较两组患者的治疗效果、不良反应的发生情况以及两组患者POMS评分。结果：小剂量MA组治疗有略高于标准MA组（66.66%vs52.38%，P＞0.05）；两组患者白细胞降低、血小板降低、贫血、GGT、严重消化道反应相比差异显著（P＜0.05），且小剂量MA组毒副作用发生情况优于标准MA组（P＜0.05）；小剂量MA组患者情绪状态量表中紧张-焦虑、抑郁-沮丧、疲劳-无力评分和总分显著优于标准MA组（P＜0.05）。结论：小剂量MA治疗AML效果确切，可有效降低毒副作用的发生，有助于改善病人的心理状态，对提升病人的生存质量及其预后的改善具有积极作用。 　　【关键词】小剂量MA；髓性白血病；疗效 　　Effect of small dose MA regimen in treatment of elderly patients with myeloid leukemia 　　[Abstract] Objective: To older patients with acute myeloid leukemia given low dose of mitoxantrone and cytarabine (MA) regimens in the treatment of discussion. Methods: 42 patients with AML received from February 2015 to January 2010 were studied. The patients were divided into two groups with 21 patients in each group. The patients were treated with standard dose of MA. The patients were treated with small dose of MA and MA group. To compare the therapeutic effect and adverse reactions of the two groups, and the POMS score of the two groups. Results: The low dose MA group was slightly higher than the standard MA group (66.66%vs52.38%, P gt; 0.05); the two groups were significantly lower than the standard MA group (P lt; 0.05), and low dose MA group (P lt; 0.05), and low dose MA group showed significantly better than the standard MA group (P lt; 0.05). Conclusion: Small dose of MA in the treatment of AML is effective, can effectively reduce the occurrence of toxic and side effects, can improve the psychological state of patients, improve the quality of life and prognosis of patients with positive effect. 　　[Key words]Low dose MA; Myeloid leukemia; Curative effect 　　急性髓性白血病（AML）每年的发生率大概在2~3人/100000人，男性患者比重稍大于女性患者，随着年纪增长发病率越高，研究证实，65岁以上老人AML的发病率大概是65岁以下老人十倍以上[1]。由于在我国社会的老龄化，AML的患者也在逐年递增。进入老年后，自身免疫降低、组织器官衰弱等原因使老年患者对标准MA方案往往不耐受，出现重度不良反应，治疗持续久后更有心理抑郁报道，对患者生存质量造成巨大困扰[2]。为了改善这种现状，我院在2010年1月—2016年2